Movement Alert｜SBP GROUP Falls 3.27% in Regular Trading, Phase 3 Nasal Polyp Drug Trial Enrollment Completed

Market Focus10-22

On October 22, SBP GROUP fell 3.27% in regular trading, trading at HK$5.185, with turnover of HK$63.54 million.

The most recent company-specific catalyst in public disclosures was the announcement that subsidiary Chia Tai Tianqing Pharmaceutical completed enrollment of all participants in the Phase 3 registration trial of TQC2731 for maintenance treatment of chronic sinusitis with nasal polyps.

TQC2731 is a TSLP-targeting antibody and was described by the company as the first domestic TSLP monoclonal antibody to enter Phase 3. The update marks a clinical development milestone, but it does not include efficacy or approval results, leaving the market to wait for later data readouts and regulatory progress. A similar movement alert published on October 22 also linked the stock's weakness to this R&D progress update while noting that further validation is still needed.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment